| Companies sponsors |
Janssen-Cilag (teclistamab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Blood Cancer UK |
| |
Myeloma UK |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
UK Myeloma Society |
| Associated public health groups |
None |
| Comparator companies |
Takeda (ixazomib) (confidentiality agreement signed, participating) |
| |
Accord Healthcare (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Aspire Pharma (bortezomib) (confidentiality agreement not signed, not participating) |
| |
• Baxter Healthcare Ltd (cyclophosphamide) (confidentiality agreement not signed, not participating) |
| |
Biocon Pharma UK (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Bristol Myers Squibb Pharmaceuticals (lenalidomide, pomalidomide) (confidentiality agreement not signed, not participating) |
| |
Cipla EU (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Dr Reddy's Laboratories (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals Europe Ltd (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Medac GmbH (bortezomib) (confidentiality agreement not signed, not participating) |
| |
MSN Laboratories Europe (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Mylan (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Pfizer (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Pharma& GmBH (panobinostat) (confidentiality agreement not signed, not participating) |
| |
Piramal Critical Care (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Ranbaxy, a Sun Pharmaceutical Company (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Sandoz (bortezomib, lenalidomide, cyclophosphamide) (confidentiality agreement not signed, not participating) |
| |
Sanofi (isatuximab) (confidentiality agreement not signed, not participating) |
| |
Sun Pharmaceutical (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Teva UK (lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Thornton & Ross (bortezomib, lenalidomide) (confidentiality agreement not signed, not participating) |
| |
Tillomed Laboratories (bortezomib) (confidentiality agreement not signed, not participating) |
| |
Zentiva (lenalidomide) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |